Adherence to hepatitis C treatment in recovering heroin users maintained on methadone

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 9, 2007, Pages 741-747

  Sylvestre, Diana L ^a,b   Clements, Barry J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Organization to Achieve Solutions in Substance Abuse (OASIS)   (United States)

Author keywords

Abstinence; Barrier; Drug use; Hepatitis C; Psychiatric disease

Indexed keywords

ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; METHADONE; RIBAVIRIN;

ABSTINENCE; ADULT; ANAMNESIS; ARTICLE; BACTERIAL PERITONITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CONVALESCENCE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; PSYCHIATRIC DIAGNOSIS; RELAPSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINALYSIS;

ADULT; ANTIVIRAL AGENTS; DIAGNOSIS, DUAL (PSYCHIATRY); DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HEROIN DEPENDENCE; HUMANS; INTERFERON ALFA-2B; MALE; MENTAL DISORDERS; METHADONE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 34547942089     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3281bcb8d8     Document Type: Article

References (27)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26 (3 Suppl 1): 62S-65S.
2. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl 1):S6-S10.
3. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl 1):S11-S19.
4. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36 (5 Suppl 1):S210-S219.
5. McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis 2001; 20:19-31.
6. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40 (Suppl 5):S276-S285.
7. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29:159-165.
8. Nunes D, Saitz R, Libman H, Cheng DM, Vidaver J, Samet JH. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res 2006; 30:1520-1526.
9. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100.
10. Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barradas M. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003; 36:1039-1046.
11. Ferrando SJ, Wall TL, Batki SL, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse 1996; 22:475-487.
12. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:117-125.
13. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000; 14:151-155.
14. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27:251-259.
15. Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, Squier C, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999; 29:824-830.
16. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994; 154:1121-1127.
17. Sylvestre DL, Zweben JE. Integrating HCV Services for Drug Users: a model to improve engagement and outcomes. Int J Drug Policy 2007, In press.
18. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-193.
19. Pianko S, McHutchison JG. Treatment of hepatitis C with interferon and ribavirin. J Gastroenterol Hepatol 2000; 15:581-586.
20. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
21. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
22. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
23. Mason BJ, Kocsis JH, Melia D, Khuri ET, Sweeney J, Wells A, et al. Psychiatric comorbidity in methadone maintained patients. J Addict Dis 1998; 17:75-89.
24. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345:215-217.
25. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36 (5 Suppl 1):S1-S2.
26. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 2000; 909:186-216.
27. Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. J Psychoactive Drugs 1991; 23:232-238.